# "Efficacy and Safety of Brimonidine Tartrate Preservative-Free Formulation in Adults With Ocular Redness"

> **NCT05360784** · PHASE3 · COMPLETED · sponsor: **Bausch & Lomb Incorporated** · enrollment: 380 (actual)

## Conditions studied

- Ocular Redness

## Interventions

- **DRUG:** Brimonidine tartrate ophthalmic solution 0.025% preservative-free formulation
- **DRUG:** Lumify® (brimonidine tartrate ophthalmic solution 0.025%)

## Key facts

- **NCT ID:** NCT05360784
- **Lead sponsor:** Bausch & Lomb Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-05-13
- **Primary completion:** 2022-11-23
- **Final completion:** 2022-11-23
- **Target enrollment:** 380 (ACTUAL)
- **Last updated:** 2024-08-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05360784

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05360784, ""Efficacy and Safety of Brimonidine Tartrate Preservative-Free Formulation in Adults With Ocular Redness"". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05360784. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*